Reuters logo
BRIEF-Abbvie's investigational HCV regimen receives FDA Breakthrough Therapy Designation
2016年9月30日 / 中午12点22分 / 1 年前

BRIEF-Abbvie's investigational HCV regimen receives FDA Breakthrough Therapy Designation

Sept 30 (Reuters) - Abbvie Inc :

* AbbVie’s investigational HCV regimen receives U.S. FDA Breakthrough Therapy Designation Source text for Eikon: Further company coverage: ;))

我们的标准:汤森路透“信任原则”
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below